

Prostate Cancer Foundation of Australia Review of the Clinical Practice Guidelines for PSA Testing

Public Comment Period

This consultation seeks written submissions from Australians who wish to comment on the *2016 Clinical Practice Guidelines for Prostate Specific Antigen (PSA) Testing and Early Management of Test-detected Prostate Cancer* ([the 2016 Guidelines](#)).

Submissions will be used to inform the development of revised guidelines to be released in 2025.

This public consultation aligns with the National Health and Medical Research Council endorsed process for guideline review. This process is overseen by a Project Steering Committee comprising consumer, community and industry representatives, a 51-member multi-disciplinary Expert Advisory Panel (EAP) and 12 EAP Working Groups.

The deadline for comments is 5pm on Friday 31 May, 2024.

[Click here](#) for more information on the public comment period.

You can make a submission [online](#), or by filling in this form and emailing or posting it to the addresses provided below.

Submit via email:

research@pcfa.org.au

Submit via post:

To the Steering Committee

Review of Guidelines for PSA Testing

PO Box 499

St Leonards NSW 1590

Privacy information

Any personal information collected via this form will be stored and used in accordance with PCFA's obligations under the Privacy Act 1988, and in accordance with the [PCFA Privacy Policy](#). All information collected will be de-identified for reporting purposes.

Privacy Collection Notice*

I have read and understood the security warning/disclaimer in the Privacy Information notice and accept the risks and conditions outlined.

* Indicates a required field



Personal / organisational information

Name

Email

Postcode *

Gender

Does this submission reflect the views of an individual, an organisation or a group? *

For Individuals only

Complete this section if you are responding as an individual. If you are responding on behalf of an organisation, click [For organisations](#). If you are responding on behalf of a support or consumer group click [For support and consumer groups](#).

Do you identify with any of the follow?

Please select any that apply

- Aboriginal and Torres Strait Islander peoples
- People living in a rural or remote area
- LGBTQIA+ people
- People from culturally and linguistically diverse communities
- None of the above

State or Territory *

Individual background *

Please select any that apply

- Consumer - I have been diagnosed with prostate cancer
- Partner – my partner has been diagnosed with prostate cancer
- Family member – a member of my family has been diagnosed with prostate cancer
- Friend – my friend has been diagnosed with prostate cancer
- Prostate cancer support group member or leader
- General Practitioner
- Industry representative
- Nurse – if yes, what is your area of specialty?

Allied Health Professional – if yes, what is your area of specialty?

Specialist clinician – if yes, what is your area of specialty?

A member of the general public – if yes, please provide more

Other - if yes, please provide more information



For Organisations only

Complete this section if you are responding on behalf of an organisation. If you are responding as an individual click [For individuals](#). If you are responding on behalf of a support or consumer group click [For support and consumer groups](#).

State or Territory *

What is the name of your organisation? *

For support and consumer groups only

Complete this section if you are responding on behalf of a support or consumer group. If you are responding as an individual, click [For individuals](#). If you are responding on behalf of an organisation, click [For organisations](#).

What is the name of your group? *

Questions about the 2016 Guidelines

Below are some general questions about the 2016 Guidelines. You don't need to answer all sections or questions, only the one that apply to you.

All questions have a 5000 character word limit, approximately 800 words.

Have the 2016 Guidelines been effective? Please explain your view.

How can the Guidelines be strengthened to improve outcomes for people impacted by prostate cancer?



Do you consider the Guidelines easy to understand? Please explain your view.

In your experience, have the 2016 Guidelines aided decision-making at the General Practice level in Australia? Please explain your view.

How can we improve the effectiveness of the Guidelines for the Australian community broadly, and for marginalised communities and at-risk groups?



Please tell us more about your experience of prostate cancer, in relationship to the guidelines and your response to the questions above.

Are there any other comments you would like the Guideline Steering Committee to consider?

How to submit your responses

Submit via email:

research@pcfa.org.au

Submit by via post:

To the Steering Committee
Review of Guidelines for PSA Testing
PO Box 499
St Leonards NSW 1590

Submissions must be received by 5pm on Monday 31 May 2024. Late submissions will not be accepted.

Thank you for your submission.

To stay up to date with the latest prostate cancer information, please visit www.prostate.org.au.